the tag tells the story

14-K gold medallion available for your patients from your Abbott Representative

PANWARFIN® SODIUM WARFARIN TABLETS

2 mg. 2½ mg. 5 mg. 7½ mg. 10 mg. 25 mg.
Subscription Service

When writing about change of address, adjustments, complaint, renewal, etc., please attach mailing label to insure prompt, efficient service. Correspondence regarding your subscription to STROKE should be addressed to:

STROKE

c/o American Heart Assoc.
Publishing Department
44 East 23rd Street
New York, N. Y. 10010

ATTACH LABEL HERE

Name (please print)

Address

City State Zip

For change of address

For uninterrupted delivery please give us four weeks' notice to process change.

Attach present label with old address and enter new address above.

the standard!

PAVABID®
(papaverine HCl, 150 mg)

it's the original sustained action papaverine HCl . . . made by MARION.

the manufacture of Pavabid Plateau CAPS® is a proprietary process for controlling the release rate of papaverine and is not available to other manufacturers.

all of the clinical studies on sustained action papaverine have been conducted with Pavabid.
Lately, he forgets.
(Did he mention it when you checked his glucose tolerance?)

A few gaps in his memory... a spell of unexplained weakness... a dizzy spell now and then: The early warnings of cerebrovascular disease are often subtle, easy for the patient to dismiss.

But they are by no means uncommon.
You are most likely to detect them, of course, in the diabetic, the hypertensive, the cardiac patient... surprisingly often during their forties and fifties.
Detecting these warnings, however, may require careful questioning, sometimes of the family as well as the patient. You can't always trust the patient to speak of them spontaneously.

It pays to be suspicious. Early diagnosis of transient ischemia means more viable vascular muscle capable of responding to the direct spasmolytic and dilating action of Cyclospasmol... a better chance to protect and maintain adequate cerebral circulation.

Cyclospasmol has a smooth, gradual onset of action. Chances for the desired result increase with continued use. It is notably free of adrenergic, cardiostimulant and other unwanted effects.

Before transient cerebral ischemia gives way to lasting damage

**Cyclospasmol**
(cyclandelate)

For long-term enhancement of cerebral blood flow

See facing page for Brief Summary
Cyclospasmol (cyclandelate)

ACTIONS: Cyclospasmol (cyclandelate) is an orally effective peripheral spasmolytic and vasodilator that acts directly on the vascular smooth musculature to produce a gradual and progressive relaxation that enhances the peripheral and cerebral blood flow. INDICATIONS: For adjunctive therapy in occlusive and vasospastic diseases of the vascular system associated with an impaired circulation, such as: intermittent claudication; arteriosclerosis obliterans; thrombophlebitis (to control associated vasospasm and muscular ischemia); nocturnal leg cramps; local frostbite; Raynaud's phenomenon; as an aid to encourage healing of diabetic and trophic ulcers of the legs; and for selected cases of ischemic cerebral vascular disease. A faster response may be expected in conditions in which vasospasm is predominant in the pathological process. The drug is not intended to substitute for an adequate medical or surgical program in the treatment of peripheral or cerebral vascular disease. It is imperative that the patient continue to follow established therapy, e.g., foot care, discontinuance of smoking, etc., while taking Cyclospasmol. Since cerebrovascular disease is diagnosed most frequently only after destruction of nerve tissue, it cannot be expected that signs and symptoms arising from an interruption of neuronal function can be completely reversed by correcting the exciting cause. Nevertheless, restoration of blood flow towards more normal levels with cyclandelate may often produce marked relief from such signs and symptoms as head noises, ringing in the ears, feeling of weakness, unsteady gait, mental confusion, temporary fluctuations in hearing acuity, poor memory and slurred speech. More important, the drug may provide prophylaxis against further circulatory embarrassment, particularly if the diminished circulation is associated with spasm of the vascular wall.

CONTRAINDICATIONS: Cyclospasmol is contraindicated in cases of known hypersensitivity to the drug. WARNINGS: 1. Cyclandelate should be used with extreme caution in patients with severe obliterative coronary artery or cerebral vascular disease, since there is a possibility that these diseased areas may be compromised by vasodilatory effects of the drug elsewhere. 2. USE IN PREGNANCY: The safety of cyclandelate for use during pregnancy or lactation has not been established; therefore, it should not be used in women or in women of childbearing age unless, in the judgment of the physician, its use is deemed absolutely essential to the welfare of the patient. 3. Although no prolongation of bleeding time has been demonstrated in humans in therapeutic dosages, it has been demonstrated in animals at very large doses. Therefore, the hazard of a prolonged bleeding time should be carefully considered when administering cyclandelate to a patient with active bleeding or a bleeding tendency. PRECAUTIONS: Since Cyclospasmol is a vasodilator, it should be used with caution in patients having glaucoma. Consult direction circular before prescribing. ADVERSE REACTIONS: Gastrointestinal distress (pyrosis, pain and eructation) may occur with Cyclospasmol. These symptoms occur infrequently and are usually mild. Relief can often be obtained by taking the medication with meals or by the concomitant use of antacids. Mild flush, headache, feeling of weakness or tachycardia may occur, especially during the first weeks of administration.

SUPPLIED: 200 mg. blue capsules in bottles of 100 and 500; 100 mg. orange tablets in bottles of 100 and 500. May we send you reprints, detailed literature or professional samples?

IVES LABORATORIES INC. 685 Third Avenue, New York, N.Y. 10017

New...

AN INTERNATIONAL BIBLIOGRAPHY OF CARDIOVASCULAR AUSCULTATION AND PHONOCARDIOGRAPHY

Compiled by
Abe Ravin, M.D. and Florence K. Frame, M.A.

A unique and authoritative compilation of journal articles 1820-1966, books, theses, dissertations, phonodiscs 1819-1968 on the sounds produced by the heart and great vessels. Over 6,000 references arranged in five parts including author and subject index.

No Previous Journal Publication

HARD COVER MONOGRAPH 31
318 PAGES PRICE: $10.00

TO ORDER USE THIS COUPON

☐ Check enclosed (Make Payable to American Heart Association)
Send me_ copies of AN INTERNATIONAL BIBLIOGRAPHY OF CARDIOVASCULAR AUSCULTATION AND PHONOCARDIOGRAPHY at $10.00 (EM262C)

Name ____________________________
Street ____________________________
City ____________________________ Zip ______
State ____________________________
MAIL TO: American Heart Association
44 East 23rd Street
New York, N. Y. 10010

(EM262CY)
Edited By: Clark H. Millikan, M.D.

Associate Editors: A. B. Baker, M.D., Fletcher McDowell, M.D.

This is the first scientific journal concerned with stroke. STROKE is a bi-monthly designed to meet today's needs of the neurologist, internist, physiatrist, cardiologist, teacher, clinical investigator and laboratory scientist in the area of cerebral vascular disease.

STROKE will publish articles on clinical conferences dealing with prevention, diagnosis, treatment and rehabilitation. In research, papers will report findings in the fields of vascular physiology, epidemiology, pathophysiology, neuroophthalmology, radiology and surgery.

To subscribe please use this coupon or write:

Publishing Department C4
American Heart Association, 44 E. 23rd Street, New York, N.Y. 10010

Please enter my subscription to STROKE.
$25 U.S. & Canada, $30 Foreign, $12.50 Residents & Interns (U.S. only).
☐ check enclosed ☐ bill me later

Please check one
☐ Neurologist ☐ Cardiologist ☐ Internist or ________________

Name

Address

City State Zip